Anti-Alanyl-tRNA synthetase (AARS Antibody), clone M6-P2E5

Alanyl-tRNA synthetase (AARS), also known as Alanine-tRNA ligase, AlaRS, or Renal carcinoma antigen NY-REN-42, and encoded by the gene AARS, is a key transfer RNA synthetase responsible for the attachment of alanine to the tRNA(Ala) for protein translation. Alanine-tRNA ligase also can edit incorrectly charged tRNA(Ala) for proper translation. Alanine-tRNA ligase is a monomer and is localized in the cytoplasm and ubiquitously expressed. Mutations in Alanine-tRNA ligase have been linked to a progressive peripheral nervous disorder called Charcot-Marie Tooth disease. Moreover autoantibodies against aminoacyl tRNA synthetases are some of the most common autoantibodies detected in autoimmune diseases with nearly 25-35% of patients having them, and some of these such as autoantibodies to Alanine-tRNA ligase have also been associated with autologous antibodies in renal carcinoma patients.

~110 kDa observed

Linear peptide corresponding to the C-terminus of human Alanyl-tRNA synthetase (AARS).

This Anti-Alanyl-tRNA synthetase (AARS Antibody), clone M6-P2E5 is validated for use in Western Blotting and Immunohistochemistry (Paraffin) for the detection of Alanyl-tRNA synthetase (AARS).

Western Blotting Analysis: 1.0 µg/mL from a representative lot detected Alanyl-tRNA synthetase (AARS) in 10 µg of HepG2 cell lysate.
Immunohistochemistry Analysis: A representative lot detected Alanyl-tRNA synthetase (AARS) in human breast cancer tissue (Prof. Ayham Alnabulsi, University of Aberdeen)

Format: Purified

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected Alanyl-tRNA synthetase (AARS) in 10 µg of HeLa cell lysate.